11 results about "Oestrogen deficiency" patented technology

The invention discloses application of PGRN in preparation of products for preventing and treating neuropsychiatric disorder related diseases caused by estrogen deficiency. The invention provides an application of a PGRN protein or a coding gene thereof or a virus expressing the coding gene thereof in preparation of a product with any one of the following functions: 1) preventing or treating or saving neuropsychiatric disorder related diseases caused by estrogen deficiency; 2) preventing or treating perimenopausal anxiety and / or depression symptoms; and 3) relieving anxiety-like behaviors and / or depression-like behaviors caused by estrogen deficiency. The application proves that the PGRN can play a role in protecting neuron damage caused by estrogen deficiency by rescuing CTSD enzyme activity and an autophagy pathway, and prompts that related medicines and measures influencing secretion and content of the PGRN can treat perimenopausal anxiety and depressive symptoms; and a new target and a new idea are provided for clinical treatment and drug development of anxiety and depression symptoms of climacteric women.

The invention discloses a bifidobacterium animalis subsp. Lactis BA-C53 and an application of the bifidobacterium animalis subsp. Lactis BA-C53 in products for improving bone health. The bifidobacterium animalis subsp. Lactis BA-C53 is classified and named as bifidobacterium animalis subsp. Lactis Bifidobacterium animalis subsp. Lactis BA-C53, the preservation number is CCTCC NO: M 2024460, the preservation unit is China Center for Type Culture Collection, and the preservation time is March 11, 2024. The bifidobacterium animalis subsp. Lactis BA-C53 can effectively improve the steady state of intestinal flora of a mouse with osteoporosis induced by estrogen deficiency, so that the relative abundance of phylum firmicalis and phylum actinomycetes is increased, the relative abundance of phylum bacteroides is reduced, and then short-chain fatty acid is generated to activate intestinal immunity and maintain the integrity of an intestinal barrier, so that the osteoporosis caused by estrogen deficiency is inhibited. Meanwhile, osteoclast differentiation can be inhibited by regulating NFATC1, RANKL and OPG pathways, then osteoporosis is relieved, and the compound can be widely applied to preparation of food and drugs.

The application discloses application of microRNA-32-5p in preparation of a medicine for preventing and treating osteoporosis, and a medicine composition taking microRNA-32-5p as an active ingredient. It is proved through experiments that knocking out the microRNA-32-5p gene significantly aggravates osteoporosis induced by estrogen deficiency; the microRNA-32-5p plays a bone protection role by promoting osteogenic differentiation of bone marrow mesenchymal stem cells. Therefore, the microRNA-32-5p can be applied to prevention and treatment of osteoporosis as a microRNA medicine.

The present application relates to the technical field of medicine, and more particularly to the application of beta-hydroxybutyric acid in the preparation of a drug for preventing and / or treating osteoporosis, including postmenopausal osteoporosis due to estrogen deficiency and diabetic osteoporosis, wherein the concentration of the beta-hydroxybutyric acid is 150 mM, the application of beta-hydroxybutyric acid in the preparation of a drug for inhibiting the differentiation of osteoclasts or inhibiting the formation of osteoclasts, wherein the beta-hydroxybutyric acid inhibits the differentiation of osteoclast precursor cells into osteoclasts, and the concentration of the beta-hydroxybutyric acid is 10 mM; the present application proves that beta-hydroxybutyric acid improves the bone microstructure of OVX mice and db / db mice, inhibits the differentiation of osteoclasts, and reduces bone resorption, thereby providing a new target for the prevention and treatment of osteoporosis.

The present invention relates to a food composition for improving and preventing estrogen deficiency, comprising a circium japonicum extract and a circium japonicum and thyme composite extract as active ingredients. The traditional Chinese medicine composition has the advantages of relieving estrogen deficiency of menopause women and improving the symptoms caused by estrogen deficiency, such as facial flushing, sweating, fatigue, anxiety, depression, dysmnesia, insomnia, increase of cholesterol in blood, weight gain, reduction of bone mineral density and the like.

This invention provides a vaginal foaming agent containing estradiol as an active ingredient, and a method for preparing the same. [Solution] The present invention provides a method for preparing estradiol into a vaginal foaming agent. The raw materials for preparing the vaginal foaming agent include a matrix material and a propellant. The raw materials for preparing the matrix material include estradiol, an oil-water amphoteric organic solvent, a hydrophobic component, a surfactant, and water. The vaginal foaming agent of the present invention has good compliance, a large contact area in the vagina, rapid release of estradiol, strong targeting of diseases caused by estrogen deficiency, rapid effect, accurate dosage, and is convenient to use.

This invention discloses a multi-functional traditional Chinese medicine composition, an oral preparation, its preparation method, and its applications. The traditional Chinese medicine composition comprises the following components in parts by weight: Epimedium 2-8 parts, dried ginger 2-8 parts, licorice 2-8 parts, ginseng 1-4 parts, Poria cocos 1-4 parts, and Salvia miltiorrhiza 1-4 parts. This traditional Chinese medicine composition has multiple effects, simultaneously preventing and treating impotence, myocardial infarction, estrogen deficiency (typical estrogen deficiency such as postmenopause) related diseases (including osteoporosis, obesity, and uterine atrophy), and anti-fatigue effects, with significant efficacy and a very high degree of applicability. Moreover, the composition is simple, with all components being medicinal and edible herbs, ensuring high safety. It can be extracted using conventional water decoction methods to produce extracts, which can then be formulated into various oral preparations, including drugs, health foods (functional foods), or other food products, possessing significant market value.

The invention relates to the field of pharmaceutical preparations, in particular to an epimedin C liposome as well as a preparation method and application thereof. The epimedin C liposome provided by the invention is prepared from epimedin C, phospholipid, steroid and a nonionic emulsifier. The invention also provides a preparation method and application of the epimedin C liposome. The epimedin C lipidosome prepared by the invention has good stability and high drug encapsulation efficiency, and experimental results show that the lipidosome can promote the generation of endogenous estradiol in a low-estrogen environment by activating aromatase, so that the development of a new dosage form of the lipidosome can reduce the administration frequency and improve the bioavailability. The traditional Chinese medicine composition can be used for preventing or delaying the perimenopausal syndrome and perimenopausal related diseases, and meanwhile, an effective and convenient treatment scheme is provided for ovarian failure or estrogen deficiency caused by bilateral ovariectomy.

The invention discloses application of Plitidepsin in preparation of a medicine for treating osteoporosis caused by estrogen deficiency, and belongs to the field of biological medicine. The cyclic oligopeptide activates an Nrf2 / HO-1 antioxidant pathway and inhibits NF-kappa B and MAPK pathways by reducing the active oxygen level in osteoclasts, thereby inhibiting osteoclast differentiation, maturation and bone resorption activity. Experiments prove that 10-40 [mu] g / kg of Plitidepsin can be applied in a subcutaneous injection manner, and can down-regulate the specific gene expression of osteoclasts and reduce bone loss.

The invention belongs to the technical field of biology, and particularly relates to a biomarker for potential treatment needing Qingshu granules and application of the biomarker. The biomarkers comprise a series of differentially expressed genes (such as Egr3, Gpr88 and Adora2a) and proteins (such as GAD67, ER beta and the like), the markers are highly associated with occurrence and development of hypertension, especially pathological mechanisms of estrogen deficiency related hypertension, so that the biomarkers are applied to preparation of novel antihypertensive drugs, hypertension is reduced through a multi-channel synergistic effect, and the antihypertensive effect is achieved. Comprising the following steps: regulating hypothalamic functions, recovering estrogen level, improving neurotransmitter balance, inhibiting oxidative stress and inflammatory response and the like; the Qingshu granules disclosed by the invention can be used as a corresponding functional medicine. The key effects of the Egr3 and the GAD67 in a central nervous system, especially in function connection of an emotion regulation brain region, are defined for the first time.

The invention provides an application of pinosin in preparation of medicines for preventing and treating osteoporosis, relates to the technical field of new applications of chemical medicines, and is technically characterized in that the application of pinosin in treatment of osteoporosis is provided, and a new way is provided for preventing and treating osteoporosis. According to the application, in-vitro intervention on mouse bone marrow-derived mononuclear / macrophages is carried out by using the pinosine, so that whether the pinosine can inhibit osteoclast differentiation or not is researched. Whether the densiferin promotes osteoblast differentiation and mineralization or not is researched by intervening mouse mesenchymal stem cells in vitro through the densiferin. According to the invention, an intraperitoneal injection administration method is also used for researching whether the denosine has a treatment effect on an estrogen deficiency osteoporosis model or not. According to the application, mice are randomly divided into a false operation group, an OVX model group, a 2mg / kg pinosine treatment group and a 10mg / kg pinosine treatment group. And performing Micro-CT and TRAP, ALP and ARS histological detection on the distal femur of the killed animals 8 weeks after modeling in each group, and evaluating the therapeutic effect of the densiferin treatment on the estrogen deficiency osteoporosis model.